Nevertheless, our in vitro experiments robustly demonstrate that SYCP2 expression modulates sensitivity to ABL1 inhibition and is required for DNA repair via TC-HR, supporting a model in which ABL1 inhibitors preferentially target SYCP2-high, platinum-resistant cancer cells. Here, SYCP2 is linked to cancer.